Industry News (Joint Venture)

CRADA Signed To Expand Cancer Vaccine Trials

Published in Cancer Weekly, May 5th, 1997

Genzyme Transgenics Corp., Framingham, Massachusetts, announced that it has signed a five-year Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI) to expand research and development activities related to idiotypic cancer vaccines.

The agreement expands Phase I clinical trials currently in progress at the NCI. Under the terms of the CRADA, Genzyme Transgenics has licensing rights to the idiotypic vaccines being developed in collaboration with the NCI.

Idiotypic vaccines contain proteins derived from individual patient tumors or from specific types of tumors. In the Phase I trials, the vaccines are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-05-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry